Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

Launched by BAYER · Jan 25, 2018

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient aged 50 years or more at aflibercept treatment initiation.
• • Treatment-naïve patients with nAMD
• • Patients who initated treatment with IVT aflibercept injection between 1st April 2014 to 31st May 2016
• • Patients that have been decided to be treated with IVT aflibercept with a minimum treatment follow-up with IVT aflibercept injection of at least 12-months, in accordance with the approved SmPC.
• • Patients who have been provided with appropriate information about the study objectives and procedures and who have given their written informed consent.
• Exclusion Criteria:
• • Patients who have previously been treated with anti-VEGF intravitreal injections, systemic anti-VEGF or pro-VEGF treatments, as well as other intravitreal steroids or steroid implants for the study eye.
• • Patients that switched to another treatment alternative different from IVT aflibercept injection during observation period of 12 months
• • Patients with another retinal disease: diabetic retinopathy, diabetic macular edema (DME), myopic choroidal neovascularization, retinal vein occlusion (RVO), central serous chorioretinopathy (CSC), angioid streaks.
• • Patients with scarring, fibrosis, or atrophy involving the center of the fovea in the study eye at treatment initiation
• • Patients with advanced cataract or advanced glaucoma
• • Patients with presence of retinal pigment epithelial tears or rips involving the macula in the study eye prior to treatment initiation.
• • Patients who do not meet the local Guideline criteria for aflibercept treatment. Contraindications listed in the SmPC must be taken into account.